These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10649904)

  • 1. [Aminoglutethimide in the treatment of metastatic breast carcinoma].
    Vasović S; Nesković-Konstantinović Z; Susnjar S; Stamatović Lj; Nesković B; Mitrović L; Jelić S
    Srp Arh Celok Lek; 1999; 127(9-10):333-7. PubMed ID: 10649904
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hormonal therapy with aromatase inhibitor in advanced breast cancer].
    Vrbanec D; Belev B; Pavlinić-Diminić V; Pezerović D; Dusper B; Plestina S; Unusić J
    Lijec Vjesn; 1998; 120(10-11):315-8. PubMed ID: 19658346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical adrenalectomy with aminoglutethimide-cortisol in the treatment of metastatic breast carcinoma.
    Paridaens R; Van Haelen C; Heuson JC
    Eur J Cancer (1965); 1980; Suppl 1():103-6. PubMed ID: 7318860
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)].
    Rieche K
    Dtsch Med Wochenschr; 1981 Oct; 106(40):1296-300. PubMed ID: 7274074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.
    Lawrence B; Santen RJ; Lipton A; Harvey HA; Hamilton R; Mercurio T
    Cancer Treat Rep; 1978 Oct; 62(10):1581-3. PubMed ID: 213192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A call for caution in the use of aminoglutethimide: negative interactions with dexamethasone and beta blocker treatment.
    Halpern J; Catane R; Baerwald H
    J Med; 1984; 15(1):59-63. PubMed ID: 6149250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast carcinoma metastases.
    Bodzin GA; Staren ED; Faber LP
    Chest Surg Clin N Am; 1998 Feb; 8(1):145-56. PubMed ID: 9515179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of metastatic breast cancer with aminoglutethimide after failure of tamoxifen].
    Brufman G; Biran S
    Harefuah; 1984 Dec; 107(12):377-99. PubMed ID: 6532917
    [No Abstract]   [Full Text] [Related]  

  • 9. [Aromatase inhibitors].
    Mauriac L; Bonneterre J
    Bull Cancer; 2000 Dec; 87 Spec No():5. PubMed ID: 11250603
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of metastasizing breast cancer with aminoglutethimide].
    Kübböck J; Ludwig H; Aiginger P; Linkesch W; Pötzi P
    Acta Med Austriaca; 1982; 9(5-6):221-6. PubMed ID: 7164757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irreversible thrombocytopenia following aminoglutethimide.
    Kissin MW; Kark AE
    Cancer Treat Rep; 1983 Sep; 67(9):849. PubMed ID: 6883365
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The replication error phenotype is associated with the development of distant metastases in hormonally treated patients with breast carcinoma.
    Chagpar A; Magliocco A; Kerviche A; Tan L; Walley B; DeCoteau JF
    Cancer; 2004 Mar; 100(5):913-9. PubMed ID: 14983485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary eosinophilia associated with aminoglutethimide.
    Bell SC; Anderson EG
    Aust N Z J Med; 1998 Oct; 28(5):670-1. PubMed ID: 9847965
    [No Abstract]   [Full Text] [Related]  

  • 15. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
    Boccardo F; Rubagotti A; Aldrighetti D; Buzzi F; Cruciani G; Farris A; Mustacchi G; Porpiglia M; Schieppati G; Sismondi P
    Cancer; 2007 Mar; 109(6):1060-7. PubMed ID: 17295293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of early distant metastatic disease in elderly patients with breast cancer.
    Chagpar AB; McMasters KM; Martin RC; Thoene C; Nurko JY; Edwards MJ;
    Am J Surg; 2006 Sep; 192(3):317-21. PubMed ID: 16920425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoglutethimide in the management of advanced breast cancer.
    Smith IE; Coombes RC; Ford HT; Gazet JC; Harmer C; Jones M; McKinna JA; Powles TJ
    Eur J Cancer (1965); 1980; Suppl 1():99-101. PubMed ID: 7318876
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe thrombocytopenia following the administration of aminoglutethimide.
    Katz ME
    Conn Med; 1984 Jul; 48(7):423-4. PubMed ID: 6467929
    [No Abstract]   [Full Text] [Related]  

  • 20. Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.
    Hultborn R; Johansson-Terje I; Bergh J; Glas U; Hallsten L; Hatschek T; Holmberg E; Ideström K; Norberg B; Ranstam J; Söderberg M; Wallgren UB
    Acta Oncol; 1996; 35 Suppl 5():75. PubMed ID: 9142972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.